Crohn’s Disease

“SSIs offer an innovative, novel approach to improving care within the context of trusted, credible scientific studies.”

~ Dr. Simon Sutcliffe, Chief Medical Officer, Qu Biologics

 COMPLETED: Crohn’s disease trial – Part #1 (Jan-6-2021)

Qu Biologics has finished “part #1” of a small Canadian patient Phase 2 clinical trial of QBECO SSI in the treatment of adults living with moderate to severe Crohn’s disease. The trial started in mid-2019 and finished in late 2020. Preliminary data analysis suggests promising positive clinical signals that QBECO works. Qu Biologics anticipates fully analyzed results by Feb-2021 and we should have a clearer picture on how to move forward then.

The aim of this trial was to further establish the safety and efficacy of the investigational drug QBECO SSI for the induction of clinical and endoscopic response and remission. QBECO SSI is intended to restore innate immune function and achieve sustained remission off all medications. In addition, this study will help to determine whether improvement in endoscopic healing is seen after 16 weeks or after 26 weeks of treatment.

For more information, check out our webinars about the trial.

Funding dependent, we anticipate that part #2 of this trial will be a multi-center, multi-national, randomized controlled trial. A timeline has not be set. Are you interested in future Crohn’s disease trial updates, please sign-up here.


See the results from our Phase 2 68-patient randomized, placebo-controlled clinical trial for the treatment of Crohn’s disease here.

Do you have Crohn’s Disease?

Qu Biologics has developed QBECO SSI, an investigational treatment designed to restore normal immune function.

Qu Biologics’ proprietary Site Specific Immunomodulators (SSIs) are investigational treatments designed to restore normal immune function in the targeted tissue to reverse the chronic inflammation underlying many chronic illnesses, including Crohn’s disease. E. coli is a bacterium that is a common cause of gastrointestinal infection. QBECO SSI is derived from components of inactivated E. coli and aims to simulate infection without causing it and, in so doing, stimulates a targeted innate immune response in the gastrointestinal tract to clear the chronic infection and dysbiosis that may underlie Crohn’s disease. Read more about QBECO SSI treatment for Crohn’s disease and how SSIs work.



Qu Biologics’ clinical trial in Crohn’s Disease

Qu Biologics has completed a 68-patient randomized, placebo-controlled clinical trial for the treatment of Crohn’s disease.  A summary of the results from this Health Canada-approved trial can be found here.

For more information on our clinical program in Crohn’s disease visit